《異動股》巨子生物(02367.HK)逆市續升逾9% 成交倍增
巨子生物(02367.HK)由五個月低位連升第三天,今天逆市重越10天線(33.6元),午後升幅曾擴至11.6%高見34.7元,現報34.05元,續升9.3%,成交倍增至647萬股,涉資2.12億元。
巨子是內地基於生物活性成分專業皮膚護理產品生產行業的領軍者。股份於去年11月初以每股24.3元來港上市,股價於今年3月下旬曾升至58.8元創上市新高遇阻,掉頭輾轉滑落,上周五跌至28.4元獲承接。該公司3月下旬公布,去年多賺21%報10.02億人民幣,每股盈利0.99元人民幣,營業額按年升逾52%至23.64億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.